Tag: Avidity Biosciences
-
Novartis’ Del-desiran Fails Phase 3, Deepening a Week of Pipeline Setbacks
Novartis’ del-desiran missed the primary endpoint in the Phase 3 HARBOR trial for DM1, raising questions about the $12 billion Avidity acquisition and the clinical translation of its AOC platform.